MGC Pharmaceuticals Ltd set to continue on strong commercial trajectory leading into 2021 proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.
TORONTO, Jan. 12, 2021 /PRNewswire/ -
Namaste Technologies Inc. ( Namaste or the Company ) (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF), a leading platform for cannabis products, accessories, and education, is pleased to announce, subject to Exchange approval, entry into the USA via CannMart.com. The Company looks forward to leveraging its VendorLink technology in collaboration with DankStop. The Company also announced that Mr. Meni Morim, CEO will be presenting at the NobleCon17 investor conference on Wednesday, January 20
th at 3:45 p.m. EST, discussing this new opportunity and the Company s expansion.
As the regulatory landscape continues to improve in the USA and globally, Namaste has begun the exploration of entering the USA via CannMart.com leveraging its proprietary VendorLink platform. The Company, through an appropriate affiliate, intends to use this expansion as a beachhead into the USA increasing its total addressable market by commencing with the sale of acces
‘A Christmas wish come true’: CBD industry celebrates as EC resumes Novel Food applications More good news for the CBD industry. The European Commission has abandoned its plans to classify non-synthetic CBD a narcotic and resumed Novel Food applications for edible CBD products.
The move came after the European Court of Justice ruled that CBD is not a narcotic drug as it
“does not appear to have any psychotropic effect or any harmful effect on human health”.
This verdict, which related to the prosecution of French e-cigarette company KanaVape, put pressure on the EC to change its decision in June to postpone the progress of CBD Novel Food applications as it decided whether to class non-synthetic CBD as a narcotic.
Shares11
Two weeks ago, I reported on the landmark ruling by the Court of Justice of the European Union (the CJEU) that cannabidiol (CBD) derived from the entire hemp plant is not a narcotic under the U.N. Single Convention on Narcotic Drugs of 1961 (the Single Convention); and thus, should be freely traded between European Union (EU) member states.
The same day that piece was published, the European Commission accepted the CJEU ruling and retracted its preliminary position on treating hemp-derived CBD and other extracts derived from the flowering tops of the Cannabis sativa L. plant as narcotics. This means that CBD ingestible products won’t be banned from the EU market and that European regulators have resumed the review of those existing CBD Novel Food Authorization applications.
Share:
PALM BEACH, Fla., Dec. 14, 2020 /PRNewswire/ In recent years, cannabis and products with cannabis components, such as CBD, are one of the hot topics in the life sciences industry. Many countries now allow the medical use of cannabis to treat numerous conditions, including chronic pain, cancer, multiple sclerosis, and many others. Additionally, more and more countries have recently allowed the recreational use of cannabis. Finally, hemp (cannabis grown without mind-altering substances), is another burgeoning industry worldwide. Though there are international treaties in place, the production, distribution, and consumption of controlled substances (including cannabis) are still traditionally regulated by each country individually (even within the EU). Some countries still consider cannabis a dangerous illicit substance. Thus the legal landscape on cannabis and cannabis products is very fragmented and complicated, making it hard to get involved in the cannabis industry. Alph